IP Library Granted Patent US 9,833,277
Granted Patent B2
US 9,833,277 · App. 12/768,544 · Granted Dec 5, 2017

Systems and methods for prostate treatment

Inventors: Michael Hoey (Shoreview, MN); John H. Shadduck (Tiburon, CA)
Assignee: NxThera, Inc.
A61B18/04A61B2018/00017A61B2018/00547A61B2018/00577A61B2218/005
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,833,277
App. No.
12/768,544
Granted
Dec 5, 2017
Kind
B2
Abstract

An energy delivery probe is provided that may include any of a number of features. One feature of the energy delivery probe is that it can apply energy to tissue, such as a prostrate, to shrink, damage, denaturate the prostate. In some embodiments, the energy can be applied with a vapor media. The energy delivery probe can include a vapor delivery member configured to extend into a transition zone prostate tissue. A condensable vapor media can be delivered from the vapor delivery member into the transition zone tissue, wherein the condensable vapor media can propagate interstitially in the transition zone tissue and be confined in the transition zone tissue by boundary tissue adjacent to the transition zone tissue Methods associated with use of the energy delivery probe are also covered.

Claims (9)

1. A method for treating benign prostatic hyperplasia (BPH), comprising:

introducing a vapor delivery member into at least one selected location in transition zone tissue of a prostate; and

injecting a condensable vapor media from the vapor delivery member into the transition zone tissue so as to ablate transition zone tissue adjacent a urethra without ablating transition zone tissue adjacent a fibromuscular stroma.

2. The method of claim 1 wherein the condensable vapor media is injected for an interval of 20 seconds or less.

3. The method of claim 1 wherein the condensable vapor media is injected at a pressure ranging from about 1 psi to 5 psi.

4. The method of claim 1 wherein the vapor delivery member is introduced transversely relative to a urethra.

5. The method of claim 1 wherein the condensable vapor media is injected in a plurality of selected locations in the transition zone tissue.

6. The method of claim 1 wherein the vapor delivery member is introduced into the transition zone tissue through a wall of a urethra from a trans-urethral probe.

7. The method of claim 1 wherein a pressure of the condensable vapor media introduction is controlled by a computer controller.

Assignments (5)
NUNC PRO TUNC ASSIGNMENT Recorded May 21, 2019
From: NXTHERA, INC.
To: BOSTON SCIENTIFIC SCIMED, INC.
Reel/Frame 049240/0378 →
RELEASE OF SECURITY INTEREST Recorded May 16, 2018
From: EAST WEST BANK
To: NXTHERA, INC.
Reel/Frame 045825/0641 →
SECURITY INTEREST Recorded Dec 10, 2015
From: NXTHERA, INC.
To: EAST WEST BANK
Reel/Frame 037265/0505 →
SECURITY INTEREST Recorded Dec 1, 2015
From: NXTHERA, INC.
To: BOSTON SCIENTIFIC CORPORATION
Reel/Frame 037183/0011 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2010
From: HOEY, MICHAEL; SHADDUCK, JOHN H.
To: NXTHERA, INC.
Reel/Frame 025491/0077 →
Continuity (2)
Provisional Application 61173108 · Apr 27, 2009
Related Publication 20100286679A1 · Nov 11, 2010